Global Multiple Sclerosis Market Size to Exceed USD 37.72 Billion by 2035 | CAGR of 3.75%

Global Multiple Sclerosis Market Size to Exceed USD 37.72 Billion by 2035

According to a Research Report Published by Spherical Insights & Consulting, The Global Multiple Sclerosis Market Size is expected to Grow from USD 25.15 Billion in 2024 to USD 37.72 Billion by 2035, at a CAGR of 3.75% during the forecast period 2025-2035.  

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the Global Multiple Sclerosis Market Size, Share, and COVID-19 Impact Analysis, By Drug Type (Immunomodulatory, Immunosuppressant, Interferons, and Corticosteroids), By Route of Administration (Oral, Parenteral, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035. Get Detailed Report Description Here: https://www.decisionsadvisors.com/reports/multiple-sclerosis-market

The multiple sclerosis (MS) market pertains to the worldwide sector dedicated to diagnosing, treating, and managing multiple sclerosis, including drugs, biologics, biosimilars, and supportive care options. Multiple sclerosis (MS) is a chronic neurological condition that impacts the central nervous system (CNS), encompassing both the brain and spinal cord. Multiple Sclerosis is marked by the immune system mistakenly targeting the myelin that protects nerve fibres. Myelin is vital for the accurate transmission of nerve signals. The attack by the immune system on myelin results in the formation of scar tissue (sclerosis) in different regions of the central nervous system (CNS). The injury interrupts the standard transmission of electrical signals along the nerves, resulting in symptoms that can differ widely among people with multiple sclerosis. Frequent signs include tiredness, decreased mobility, feelings of numbness or tingling, weakness in muscles, difficulties with movement coordination and balance, vision difficulties, along with cognitive and emotional concerns. The worldwide rise in the disease's prevalence and the identification of disease-modifying treatments (DMTs) that postpone its progression and improve symptom management are driving factors in the market's growth. The worldwide multiple sclerosis market is expected to grow due to the rising incidence of the disease and heightened awareness promoted by various governmental and non-governmental organisations. However, high treatment expenses, limited access in low-income regions, adverse drug side effects, and patent expirations enabling generics to enter the market and reduce profitability are several challenges to market growth.

The immunosuppressant segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.       

Based on the drug type, the multiple sclerosis market is divided into immunomodulatory, immunosuppressant, interferons, and corticosteroids. Among these, the immunosuppressant segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The additional advantages of the medications include excellent efficacy, few side effects, and efficient administration at low dosages, all of which contribute to the market's growth.

The oral segment dominated the market in 2024 and is anticipated to grow at a significant CAGR during the forecast period.     

Based on the route of administration, the multiple sclerosis market is segmented into oral, parenteral, and others. Among these, the oral segment dominated the market in 2024 and is anticipated to grow at a significant CAGR during the forecast period.  This is because both physicians and patients favour oral medications over injectable ones.

Asia Pacific is expected to hold the majority share of the global multiple sclerosis market during the forecast period.       

Asia Pacific is expected to hold the majority share of the global multiple sclerosis market during the forecast period. This is due to increased government initiatives to help the local Multiple Sclerosis community, better healthcare infrastructure, a large and untapped patient population, and increased disposable income. Furthermore, several organisations have increased funding for this kind of research, which expedites the development and testing of medications and treatments for multiple sclerosis.

North America is anticipated to grow at the fastest pace in the global multiple sclerosis market during the forecast period. This is because of its high multiple sclerosis prevalence, state-of-the-art medical facilities, availability of innovative medications, higher R&D investment, and advantageous reimbursement rules.

Major vendors in the global multiple sclerosis market are Actelion Pharmaceuticals Ltd., Active Biotech AB, Bayer AG, Biogen Inc., Celgene Corporation, EMD Opexa Therapeutics Inc., GlaxoSmithKline plc., Innate Immunotherapeutics, InnoBioscience LLC, Merck and Co., Novartis AG, Pfizer Inc., Sanofi, Synthetic Biologics Inc., and others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development   

• In November 2025, TYRUKO (natalizumab-sztn), the first and only FDA-approved multiple sclerosis biosimilar, was introduced by Sandoz in the United States. It is anticipated to increase patient access while lowering treatment costs, and refers to Biogen's Tysabri.

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the multiple sclerosis market based on the below-mentioned segments: 

Global Multiple Sclerosis Market, By Drug Type

• Immunomodulatory
• Immunosuppressant
• Interferons
• Corticosteroids

Global Multiple Sclerosis Market, By Route of Administration

• Oral
• Parenteral
• Others

Global Multiple Sclerosis Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa